Seven Eight Capital LP lessened its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 73.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,500 shares of the specialty pharmaceutical company’s stock after selling 12,400 shares during the period. Seven Eight Capital LP’s holdings in Jazz Pharmaceuticals PLC were worth $700,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. US Bancorp DE raised its holdings in Jazz Pharmaceuticals PLC by 94.4% during the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the period. Envestnet Asset Management Inc. raised its holdings in Jazz Pharmaceuticals PLC by 43.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the period. Gargoyle Investment Advisor L.L.C. acquired a new stake in Jazz Pharmaceuticals PLC during the 2nd quarter worth about $206,000. Janney Montgomery Scott LLC acquired a new stake in Jazz Pharmaceuticals PLC during the 2nd quarter worth about $211,000. Finally, Brighton Jones LLC acquired a new stake in Jazz Pharmaceuticals PLC during the 2nd quarter worth about $213,000. Hedge funds and other institutional investors own 88.24% of the company’s stock.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 151.48 on Friday. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The firm has a market cap of $9.10 billion, a P/E ratio of 23.33 and a beta of 1.13. The company has a 50-day moving average price of $149.01 and a 200-day moving average price of $150.05.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. During the same quarter last year, the firm earned $2.67 EPS. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current year.
Several analysts have issued reports on JAZZ shares. HC Wainwright started coverage on Jazz Pharmaceuticals PLC in a report on Friday, August 25th. They set a “neutral” rating and a $144.00 price objective on the stock. Cowen and Company restated an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. BidaskClub upgraded Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Royal Bank Of Canada set a $210.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, June 27th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $180.96.
COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Equities Focus and is owned by of Equities Focus. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.equitiesfocus.com/2017/09/17/jazz-pharmaceuticals-plc-jazz-holdings-cut-by-seven-eight-capital-lp.html.
In related news, EVP Suzanne Sawochka Hooper sold 420 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $160.00, for a total value of $67,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The disclosure for this sale can be found here. In the last three months, insiders sold 8,717 shares of company stock worth $1,346,617. 4.30% of the stock is owned by insiders.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.